This Month in JNM

Radioembolization dosimetry: Traino and colleagues offer an overview of locoregional ⁹⁰Y radioembolization techniques and absorbed doses in liver tumors, providing background and context for a related article in this issue of JNM.Page 509

Breast tumor blood flow: Cochet and colleagues use ¹⁸F-FDG PET to evaluate the relationship of tumor blood flow and glucose metabolism with angiogenesis and proliferation markers in newly diagnosed breast cancer.Page 512

PET and CT perfusion in NSCLC: Sauter and colleagues investigate correlations between glucose metabolism registered by ¹⁸F-FDG PET/CT and tumor perfusion quantified by volume perfusion CT and immunohistochemical markers in patients with non–small cell lung cancer.Page 521

PET as surrogate biomarker in NSCLC: Bengtsson and colleagues assess the predictive value of early-treatment ¹⁸F-FDG PET for overall survival in non–small cell lung cancer patients treated with a targeted drug.Page 530

¹¹C-acetate in localized prostate cancer: Mena and colleagues compare ¹¹C-acetate PET/CT in prostate cancer, benign prostate hyperplasia, and normal prostate tissue with results from multiparametric MRI, whole-mount histopathology, and clinical markers.Page 538

Parametric PET/MRI: Park and colleagues report on the performance of parametric fusion PET/MRI based on ¹¹C-choline PET/CT and apparent diffusion coefficient MRI maps for identification of primary prostate cancer.Page 546

Amino acid PET cost effectiveness: Heinzel and colleagues analyze the practical aspects of clinical use of amino acid PET, compared with MRI alone, for surgical resection of high-grade gliomas, from the perspective of the German health insurance system.Page 552

Artery-specific SPECT/CT partition model: Kao and colleagues describe and validate an image-guided personalized predictive dosimetric technique for ⁹⁰Y radioembolization, integrating catheter-directed CT hepatic angiography, ^99mTc-macroaggregated albumin SPECT/CT, and partition modeling.Page 559

PET and GIST therapy: Van den Abbeele and colleagues explore correlations between metabolic response assessed by ¹⁸F-FDG PET and objective response, glucose transporter type 4 expression, and genotype in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib mesylate therapy.Page 567

Coronary artery plaque metabolic imaging: Cheng and colleagues use coregistered PET and coronary CT angiography to examine ¹⁸F-FDG uptake at culprit sites of acute myocardial infarction after percutaneous coronary stenting.Page 575

SPECT vs. MRI in cardiomyopathy: Xie and colleagues compare electrocardiogram-gated blood-pool SPECT for assessment of left and right ventricular ejection fractions, end-diastolic volumes, and end-systolic volumes with MRI results in patients with dilated cardiomyopathy.Page 584

PET indices for AD: Caroli and colleagues compare the relative abilities of three ¹⁸F-FDG PET data analysis techniques to distinguish patients with early Alzheimer disease dementia or progressive mild cognitive impairment from cognitively normal adults.Page 592

PET and endotoxin administration: Hannestad and colleagues use ¹⁸F-FDG PET to identify human brain regions involved in the response to endotoxin administration, with results that enhance understanding of the relationship between depression and systemic inflammation.Page 601

SiPM PET/MRI: Yoon and colleagues describe the development and architecture of a system based on multichannel silicone photomultiplier arrays to allow simultaneous MRI and PET.Page 608

PET marrow RIT dosimetry: Schwartz and colleagues detail and validate a method for directly estimating red marrow activity concentration and self-dose components of absorbed radiation dose to red marrow in radiotherapy, based on PET/CT of two ¹²⁴I-labeled antibodies.Page 615

Improving ¹¹C-PiB PET quantification: Zhou and colleagues use a recently developed relative equilibrium–based graphical plot method to enhance and simplify the 2 most commonly used methods for quantification of ¹¹C-Pittsburgh compound B PET.Page 622

PET and trastuzumab response: Kramer-Marek and colleagues describe a small-animal study on the ability of ¹⁸F-FBEM PET Affibody imaging to quantify changes in receptor expression and to predict responses to trastuzumab therapy.Page 629

Imaging diverse disease biomarkers: Busch and colleagues detail an in vivo spectral multiplexing approach for monitoring interactions among different molecules via near-infrared fluorescent Förster resonance energy, with implications in inflammation, cancer, and neurodegenerative diseases.Page 638

HSV1716 and ¹³¹I-MIBG therapy: Sorensen and colleagues report on the development of noradrenaline transporter gene–infected cells for combined targeted radiotherapy.Page 647

MI training for NM residents: Graham and Jacene review recent curriculum recommendations for residency training in molecular imaging and nuclear medicine.Page 655

ON THE COVER

Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling has been shown to achieve high clinical success rates for safe and effective ⁹⁰Y radioembolization. In the example illustrated, sublesional dosimetry with left radioembolization lobectomy intent was performed for a patient with recurrent hepatocellular carcinoma.See page 563.

• © 2012 by the Society of Nuclear Medicine, Inc.